

CLAIMS

1. An antibody or antigen-binding fragment thereof, comprising:

ss) a heavy chain variable region comprising 3 CDR sequences of SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43; and a kappa light chain variable region comprising 3 CDR sequences of SEQ ID NO: 377, SEQ ID NO: 45, and SEQ ID NO: 46.

2. The antibody or antigen-binding fragment thereof of claim 1, comprising:

ss) a heavy chain variable region comprising SEQ ID NO: 349 and a light chain variable region comprising SEQ ID NO: 350.

3. An antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising

SEQ	ID	NO:	380
-----	----	-----	-----

(QVQLQESGPGLVKPSXTLSLTCXVXGYSITSDYAWNWRQXPGKGLEWIGYISHSGS
TSYNPSLKS RVTISRDTSKNQFSLKLSSVTAADTAVYYCARSLGRRWYFDVWGQGT
TVTVSS), wherein the X at position i (i=16, 23, 25 and 41) of SEQ ID NO: 380 is referred as X_{Hi}, wherein X_{H16} is E or Q, X_{H23} is A or T, X_{H25} is S or Y, X_{H41} is H or P; and

a light chain variable region comprising

SEQ	ID	NO:	381
-----	----	-----	-----

(DIXMTQSPXSLXXXXGXXXXIXCKSSQSLXSSTQKNYLAWYXQKPGXXPXLLIYF
ASTRDSGVPXRFSGSGSGTDFTLXISXXXXEDLXXYFCQQHYIIPFTFGQGTKLEIK),
wherein the X at position i (i=3, 9, 12, 13, 14, 15, 17, 18, 19, 20, 22, 31, 43, 48, 49, 51, 66, 80, 83, 84, 85, 86, 90 and 91) of SEQ ID NO: 381 is referred as X_{Li}, wherein X_{L3} is V or Q, X_{L9} is D, L or S, X_{L12} is A, S or P, X_{L13} is A or V, X_{L14} is S or T, X_{L15} is L, V or P, X_{L17} is D or E, X_{L18} is R or P, X_{L19} is A or V, X_{L20} is S or T, X_{L22} is N, T or S, X_{L31} is Q, X_{L43} is Q or L, X_{L48} is Q or K, X_{L49} is A, P or S, X_{L51} is K or Q, X_{L66} is S or D, X_{L80} is K or T, X_{L83} is R or S, X_{L84} is L or V, X_{L85} is Q or E, X_{L86} is A or P, X_{L90} is A or G, X_{L91} is T or V.

4. The antibody or antigen-binding fragment thereof of claim 1, further comprising an immunoglobulin constant region, optionally a constant region of human Ig, or optionally a constant region of human IgG.

5. The antibody or antigen-binding fragment thereof of claim 1, which is a Fab, a Fab', a F(ab')₂, a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)₂, a single-chain

antibody molecule (scFv), a camelized single domain antibody, a nanobody, a domain antibody, and a bivalent domain antibody.

6. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment is linked to one or more conjugates, optionally, wherein the conjugate is covalently attached either directly or via a linker.

7. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier.

8. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof of claim 1.

9. A vector comprising the isolated polynucleotide of claim 8.

10. A host cell comprising the vector of claim 9.

11. The antibody or antigen-binding fragment thereof of claim 1 for use in treating a disease or condition in a subject that would benefit from modulation of CD276 activity, wherein a therapeutically effective amount of the antibody or antigen-binding fragment thereof is to be administered to the subject.

12. The antibody or antigen-binding fragment thereof for use of claim 11, wherein the disease or condition is cancer, adaptive immune disease, autoimmune disease, inflammatory disease, or infectious disease.

13. The antibody or antigen-binding fragment thereof of claim 1 for use in modulating CD276 activity in a CD276-expressing cell, wherein the CD276-expressing cell is to be exposed to the antibody or antigen-binding fragment thereof.

14. The antibody or antigen-binding fragment thereof of claim 6, which comprises a heavy chain variable region comprising SEQ ID NO: 367; and a light chain variable region comprising SEQ ID NO: 373.